A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS

被引：0
|
作者：
Shah, S. N. [1 ]
Wissinger, E. [2 ]
Ballew, N. [2 ]
Hepp, Z. [3 ]
机构：
[1] Astellas Pharma Inc, Northbrook, IL USA
[2] Xcenda LLC, Palm Harbor, FL USA
[3] Seattle Genet, Bothell, WA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN40
引用
收藏
页码：S443 / S443
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of PD-1/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis
    Zhang, Dongli
    Shen, Chong
    Zhang, Weichuan
    Chen, Haibin
    Zhao, Jianjun
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [22] FIRST-LINE TREATMENT PATTERNS AMONG PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (LA/MUC): A SYSTEMATIC LITERATURE REVIEW
    Kearney, M.
    Zhang, L.
    Hubscher, E.
    Musat, M.
    Harricharan, S.
    Wilke, T.
    VALUE IN HEALTH, 2022, 25 (12) : S414 - S414
  • [23] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen, Wen
    Zhang, Yong
    Zhang, Hua
    Chen, Yingshuang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 969 - 978
  • [24] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen Wen
    Yong Zhang
    Hua Zhang
    Yingshuang Chen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 969 - 978
  • [25] Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Yin, Gaofei
    Guo, Wei
    Duan, Hanyuan
    Huang, Zhigang
    CLINICAL OTOLARYNGOLOGY, 2021, 46 (05) : 1013 - 1020
  • [26] Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI).
    Shah, Manasee
    Devine, Jacob
    Wang, Sam
    Hepp, Zsolt
    Shah, Sonali
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR).
    Kearney, Mairead
    Macmillan, Tom
    Poritz, Julia
    Schreiber-Gosche, Sherrie
    Musat, Mihaela Georgiana
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [28] Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy
    Morgans, Alicia K.
    Grewal, Simrun
    Hepp, Zsolt
    Fuldeore, Rupali
    Odak, Shardul
    Macahilig, Cynthia
    Shillington, Alicia C.
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : 543 - 552
  • [29] Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis
    Ding, Jianqiao
    Liu, Zheyu
    Ning, Jing
    Sun, Nan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (03) : 259 - 267
  • [30] The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis
    Wang, Bi-Cheng
    Cao, Ru-Bo
    Fu, Chen
    Chen, Wang-Bing
    Li, Pin-Dong
    Lin, Guo-He
    Qian, Xiao-Jun
    Li, Yun-Tian
    Liu, Quentin
    ORAL ONCOLOGY, 2020, 104
12345